# NAD+: Research Overview — aminopeptides.net > A literature summary of NAD+ (nicotinamide adenine dinucleotide): its role as a redox coenzyme and sirtuin substrate, age-related decline, clinical trial data on precursors NMN and NR, and honest notes on what the human evidence does and does not show. The cell's central redox carrier and a substrate for the sirtuins, PARPs, and CD38 that govern DNA repair and aging — what the published research on NAD+ and its precursors actually shows. ## The short version NAD+ stands for **nicotinamide adenine dinucleotide**. It is not a peptide — it is a coenzyme, a small molecule present in every living cell. It plays two distinct roles: it shuttles electrons through the biochemical reactions that generate ATP (energy), and it acts as a *consumed substrate* for signaling enzymes — most notably the sirtuins, which regulate gene expression and stress response, and the PARPs, which repair damaged DNA. NAD+ declines with age. The decline appears partly driven by rising levels of an enzyme called CD38, which consumes NAD+ more aggressively as we grow older [16]. The working hypothesis in aging research is that this decline contributes to the metabolic dysfunction and reduced stress resilience that characterize cellular aging, and that restoring NAD+ levels — most practically by supplementing with precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) — might slow some of these effects. The human evidence is real but measured. Precursor supplementation reliably raises blood NAD+ [14][17]. Whether that translates to meaningful clinical outcomes — longer lives, fewer diseases, better functional aging — is still an open question as of a 2025 Nature Metabolism review [13]. This page lays out what is established, what is promising but unproven, and where the honest uncertainty lies. ## What it is NAD+ is a dinucleotide: two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by two bridging phosphate groups. Its molecular formula is C21H27N7O14P2. The oxidized form is written NAD+ (an electron acceptor); the reduced form, which has accepted electrons and a hydrogen, is NADH (an electron donor). Together the NAD+/NADH couple is the primary redox workhorse in cellular energy metabolism. NAD+ is endogenous — your body makes it from dietary precursors (tryptophan, nicotinic acid, nicotinamide, NMN, NR) via the salvage and de novo biosynthesis pathways. It is not a drug. It is sold as a dietary supplement in capsule form and, in some settings, as an intravenous infusion. Its schema.org type is DietarySupplement, not Drug. **NAD+ versus its precursors.** A key distinction for reading the literature: oral NAD+ itself is not efficiently taken up intact by cells; the consensus view is that NMN and NR (both of which enter cells and are converted to NAD+ intracellularly) are the rational oral strategy for raising intracellular NAD+ levels. When this desk cites a study using NMN or NR, it says so explicitly — the precursors and NAD+ itself are not the same intervention. ## How it works NAD+'s biological functions fall into two broad categories. **Redox carrier.** In glycolysis, the TCA cycle, and oxidative phosphorylation, NAD+ accepts electrons (becoming NADH), which are then passed to the mitochondrial electron transport chain to drive ATP synthesis. Without adequate NAD+, this central energy-generating pathway runs inefficiently. **Signaling substrate.** Several families of enzymes consume NAD+ as they carry out their functions: - *Sirtuins (SIRT1–SIRT7)*: NAD+-dependent deacylases that remove acetyl groups from histones and other proteins, regulating gene expression, mitochondrial biogenesis, stress response, and inflammation. Sirtuin activity declines when NAD+ is low. - *PARPs (particularly PARP1)*: Poly(ADP-ribose) polymerases that use NAD+ to ADP-ribosylate proteins in response to DNA strand breaks. High PARP activity (during genomic stress) can rapidly deplete the local NAD+ pool. - *CD38/CD157*: NAD-consuming ectoenzymes that rise with age and inflammation, partly explaining the age-associated decline in NAD+ [16]. - *NAMPT (nicotinamide phosphoribosyltransferase)*: The rate-limiting enzyme in the NAD+ salvage pathway; its activity determines how efficiently the cell recycles NAD+ from nicotinamide. Tissue NAD+ declines with age in multiple model organisms and in humans, and that decline is mechanistically linked to reduced sirtuin activity, impaired DNA repair, and metabolic dysfunction [16]. ## What the research shows **Foundational review (2021).** A Nature Reviews Molecular Cell Biology analysis of NAD+ metabolism and aging across yeast, worms, mice, and humans established that declining NAD+ with age is linked to metabolic dysfunction and disease susceptibility [16]. It identified the three main consumer families — sirtuins, PARPs, CD38 — and framed NAD+ restoration as a candidate aging-biology strategy. **NMN in prediabetic women (2021).** A Science paper (placebo-controlled, 10 weeks of oral NMN at 250 mg/day) found significantly improved **muscle insulin sensitivity** in prediabetic postmenopausal women, assessed by hyperinsulinemic-euglycemic clamp — a direct measure of insulin action in muscle. Body composition and HbA1c did not change [15]. This is one of the few well-controlled human mechanistic studies demonstrating a tissue-level metabolic effect of an NAD+ precursor. **Dose-response NR study (2019).** In a randomized, double-blind, placebo-controlled study of 100–1000 mg/day of NR (nicotinamide riboside) over 8 weeks in healthy overweight adults, whole-blood NAD+ rose dose-dependently by approximately 22%, 51%, and 142% at the three doses [17]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism; no significant adverse events at any dose. This confirmed that oral NR is a well-tolerated, dose-scalable NAD+ booster at the blood level. **NMN dose-ranging multicenter RCT (2023).** In a multicenter, double-blind, placebo-controlled, parallel-group trial of 300, 600, or 900 mg/day of NMN for 60 days in healthy middle-aged adults, blood NAD+ rose significantly versus placebo at both 30 and 60 days across all NMN groups (p≤0.001); walking distance and quality-of-life scores improved; 600 mg/day was identified as the optimal dose [14]. **2025 Nature Metabolism review.** The most current authoritative synthesis of the human clinical evidence concluded that human trials have shown **limited efficacy** in translating NAD+ blood elevation to clinical endpoints, that age-related NAD+ decline has been consistently observed only in a limited number of human studies, and that tissue-specific NAD+ dynamics remain sparse [13]. The review underscored the need for more human studies of systemic and tissue-specific NAD+ metabolism rather than continued extrapolation from rodent work. ## Reported effects, cautions & safety No peer-reviewed or aggregated community-anecdote data for NAD+ supplementation were compiled in this desk's source material; the entries below reflect documented uncertainties and cautions from the published literature. **Key uncertainties and cautions.** - *Oral NAD+ absorption*: Most researchers consider direct oral NAD+ an inefficient way to raise intracellular NAD+, because the intact molecule is not well absorbed. Precursors (NMN, NR) are considered the rational oral strategy. Some products sold as "NAD+" capsules may primarily deliver nicotinamide, which is converted to NAD+ via the salvage pathway. - *Blood elevation versus tissue and clinical endpoints*: Raising blood NAD+ with precursors is well documented. Whether that reliably raises NAD+ in specific tissues (muscle, brain, liver) in humans, and whether that translates to clinical benefit, are much less established — the 2025 review is explicit on this point [13]. - *Rodent-to-human translation gap*: Much of the strongest longevity and anti-aging data comes from model organisms and may not extrapolate to humans. Human lifespans and metabolic rates differ from those of mice in ways that complicate dose extrapolation. - *IV NAD+ infusions*: Marketed aggressively in wellness settings, IV NAD+ infusions rest on minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma, and infusions can cause chest discomfort, abdominal cramping, flushing, and nausea if administered too quickly. A compounded injectable NAD+ product has been subject to a Class I FDA recall for elevated bacterial endotoxin. - *Cancer biology concern (theoretical)*: NAD+ supports energy metabolism in all proliferating cells, including malignant ones. NAD+ in oncology has dual, context-dependent roles — both protective (DNA repair) and potentially tumor-supportive. This is a theoretical concern flagged in the academic literature for cancer populations. - *NMN regulatory status*: The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a new drug, creating marketplace uncertainty about its supplement status in the United States. - *Product quality*: Supplement-grade NAD+ precursor products vary widely in actual content and purity; third-party testing is not guaranteed. ## Where NAD+ fits in this desk NAD+ sits in an unusual position on this desk: it is the most biochemically fundamental of the three entries — every cell in every organism depends on it — but it is also the one with the most modest translation to hard human clinical outcomes so far. Semaglutide has Phase 3 trials; MOTS-c has a mechanistically novel animal record; NAD+ has consistent evidence of precursor-driven blood elevation and some early mechanistic wins in muscle insulin sensitivity [15], but the clinical-endpoint story is still being written. The connection to the metabolic-and-cellular-aging theme of this desk is direct: NAD+ is the common currency of the mitochondrial electron transport chain, the substrate for the sirtuins that MOTS-c activates indirectly through AMPK, and the cofactor for the DNA-repair enzymes whose decline tracks aging across species. Understanding it is part of understanding why the other two compounds are researched. See the [comparison page](/compare) for how all three line up. --- An independent reading desk for the published biology of metabolic aging — citations, not prescriptions.